Navigation Links
Amylin Pharmaceuticals Reports 2007 Financial Results
Date:1/28/2008

ember 31, 2007, compared to $63.8 million for the same period in 2006.

Net loss was $76.9 million, or $0.57 per share, for the quarter ended December 31, 2007, compared to a net loss of $58.4 million, or $0.45 per share, for the same period in 2006.

Fourth quarter highlights

Highlights of Amylin's fourth quarter include the following:

-- Positive results from a 24-week study of monotherapy, or stand alone,

BYETTA in drug nave patients with type 2 diabetes. The Company plans

for a regulatory submission for a monotherapy indication to the U.S.

Food and Drug Administration, or FDA, in the first half of 2008.

-- Positive results from a 30-week comparator study of exenatide once

weekly injection and BYETTA taken twice daily in patients with type 2

diabetes. The Company anticipates a regulatory submission to the FDA by

the end of the first half of 2009.

-- Positive results from a 24-week proof-of-concept study with the

combination treatment of pramlintide, an analog of human amylin, and

metreleptin, an analog of human leptin in overweight or obese subjects,

validating the Company's novel integrated neurohormonal treatment of

obesity (INTO) strategy. The Company plans for additional clinical

development in 2008, including the initiation of a Phase 2B study.

Year ended December 31, 2007

Total revenue for the year ended December 31, 2007 was $781.0 million. This includes net product sales of $701.5 million, consisting of $636.0 million for BYETTA and $65.5 million for SYMLIN. This compares to total revenue of $510.9 million for the same period in 2006, including net product sales of $474.0 million consisting of $430.2 million for BYETTA and $43.8 million for SYMLIN.

Revenues under collaborative agreements were $79.5 million for the year ended December 31, 2007, compared to $36.8 million for the same period in 20
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
2. Amylin Pharmaceuticals to Present at Research & Development Day
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market is ... from 2014 to 2019. , The global digital PCR (dPCR) and ... from 2014 to 2019. Although the mature markets such as the ... PCR (dPCR) and qPCR market the Asia-Pacific region is expected to ... The growth of the digital PCR (dPCR) and qPCR market is ...
(Date:3/5/2015)... March 05, 2015 AxoGen, Inc. ... on the peripheral nerve repair market, reported record revenue ... 31, 2014 compared to $2.98 million in the year-ago ... growth strategies. , “Our strong fourth quarter revenue ... nerve repair products which is driving increased surgeon adoption ...
(Date:3/5/2015)... March 05, 2015 Rhode Island Medical Imaging ... in a row to support the Providence College (PC) women’s ... covered the purchase of the ‘Think Pink’ uniforms, which were ... East Conference opponent DePaul University at Alumni Hall/Mullaney Gymnasium in ... our support of the PC women’s basketball’s ‘Pink Out’ event,” ...
(Date:3/5/2015)... Santa Rosa, CA (PRWEB) March 05, 2015 ... Like a SuperPro! The series aims to teach viewers ... indoor garden with hydroponics. Grow Like a SuperPro takes you ... in between. From how to clone, to how to prune ... of growing. They are offering the whole series for download ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... in healthcare communications and education, announced today its ... (AMP), the nation’s only medical conference designed for ... ischemia and lower limb amputation due to vascular ... family of innovative, evidence-based publications and CME activities ...
Breaking Medicine News(10 mins):Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3
... Pollution in State , , ... today approved two diesel truck regulations that will dramatically cut ... are the first of their kind in the United States, ... estimates that the truck regulations are expected to save 9,400 ...
... heart seen, study says , , FRIDAY, Dec. 12 (HealthDay News) ... will prove to be a valuable new weapon in the ... the drug, known as lorcaserin, resulted in substantial weight loss ... completely novel mechanism and we think it can bring very ...
... Dec. 12 For every parent who wants ... gift designed to provide higher,self-confidence, better academic results ... studies have proven that early readers have,more confidence, ... and,later in life. According to a national ...
... tumor characteristics help fine-tune treatment, study says , , FRIDAY, ... in predicting breast cancer risk, recurrence risk and response ... breast density and tumor size, a panel of experts ... teleconference Friday at the annual San Antonio Breast Cancer ...
... AURORA, Ohio, Dec. 12 PartsSource, the nation,s leading,supplier of ... the 100 fastest growing companies in Ohio by the ... third year in a row.,PartsSource placed 14th on this year,s ... award each year they were eligible. , ...
... using special program saw all injuries cut by a ... -- A good warm-up program may dramatically reduce sports ... the Norwegian School of Sport Sciences found that focusing ... cut injuries by a third among almost 1,900 teenage ...
Cached Medicine News:Health News:California Rules to Cut Diesel Truck Pollution Called Most Sweeping in U.S. 2Health News:Experimental Weight-Loss Pill Passes Early Test 2Health News:Experimental Weight-Loss Pill Passes Early Test 3Health News:VIDEO from Medialink and Your Baby Can Read: Early Literacy in Children ... Proven Path to Success 2Health News:Progress Made in Predicting Breast Cancer Risk 2Health News:Progress Made in Predicting Breast Cancer Risk 3
(Date:3/5/2015)... , March 5, 2015  ContraVir Pharmaceuticals, Inc. ... on the development and commercialization of targeted antiviral therapies, ... th Annual ROTH Conference, to be held March ... James Sapirstein , Chief Executive ... during his live presentation and will be available to ...
(Date:3/5/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... announced today that Atlanta -based Shepherd ... spinal cord injury and brain injury, has commenced enrollment ... progenitor cells) in newly injured patients with sensory and ... The Phase 1/2a trial follows the successful completion ...
(Date:3/5/2015)... and VANCOUVER, British Columbia , March ... 20B OTCQB: BMKDF) -- The ultimate goal in the ... is capable of detecting tumors before they become disruptive, ... development of such an assay has been the ... industry. Although many breakthrough diagnostics have been invented such ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4
... designed to travel a full 120 degrees, from ... wherever you release the rotating hand grip locking ... the handle with no need to ever go ... of system was designed to mimic the natural ...
Designed for Bariatric usage. Prevents arm or leg dropout during surgical procedures. Dimensions are 16"Lx10"H come in pairs. Optional gel pad available (BD2245)...
Designed to prevent arm or legs from dropouts during surgical procedures. Dimensions are 8"H x16"L. These come as pairs. Optional gel pads(BD2245)....
... Corporation offers a quality line ... to adults. Armboard covers are ... assuring easy cleaning while reducing ... Choose from three options: Disposable ...
Medicine Products: